title: Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging.
abstract: Erlotinib is a reversible epidermal growth factor receptor tyrosine kinase inhibitor used to treat advanced non-small cell lung carcinoma patients who have shown progression on at least 1 prior chemotherapy regimen. Most of the patients on erlotinib show cutaneous adverse effects. We report the 18F-FDG PET/CT findings in a case of metastatic non-small cell lung carcinoma on erlotinib chemotherapy with developed skin toxicity.
authors.affiliation: From the Department of Nuclear Medicine and PET, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Kunal
authors.initials: K
authors.lastname: Kumar
authors.forename: Harmandeep
authors.initials: H
authors.lastname: Singh
authors.forename: Ravi Kant
authors.initials: RK
authors.lastname: Gupta
authors.forename: Chandrasekhar
authors.initials: C
authors.lastname: Bal
authors.forename: Rakesh
authors.initials: R
authors.lastname: Kumar
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D011799:Quinazolines / Q000009:adverse effects*; D019275:Radiopharmaceuticals; D012871:Skin Diseases / Q000000981:diagnostic imaging* / Q000209:etiology; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000069347:Erlotinib Hydrochloride